CVS Health Corporation announced its financial results for the second quarter of 2025, reporting a total revenue increase to $98.9 billion, an 8.4% rise compared to the prior year. The company's GAAP diluted earnings per share $(EPS)$ decreased to $0.80 from $1.41 in the previous year, influenced by two litigation charges related to past business practices. The adjusted EPS remained steady at $1.81 compared to the prior year. The company also updated its full-year 2025 guidance, adjusting the GAAP diluted EPS range to $3.84 to $3.94, down from the previous range of $4.23 to $4.43. However, the adjusted EPS guidance range was raised to $6.30 to $6.40 from $6.00 to $6.20. Furthermore, CVS Health increased its cash flow from operations guidance to at least $7.5 billion, up from approximately $7.0 billion. Key operational developments included Aetna's advancements in care navigation, CVS Pharmacy's agreement to acquire certain prescription files and store locations from Rite Aid, and CVS Caremark's market-leading innovations during a strong renewal and sales season.